SEATTLE, May 3 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. today announced that Vaughn B. Himes, Ph.D. has been appointed Senior Vice President of Technical Operations and will be a member of the company’s Executive Management Committee. Dr. Himes replaces Mark Young, who has retired from the company. Dr. Himes’ expertise in commercialization, manufacturing, technical operations, process development, scale-up and the product approval process comes from years of experience with a wide range of pharmaceutical and biotech companies.
“We’re very pleased that Vaughn will guide ZymoGenetics’ manufacturing and technical operations. We value his years of industry expertise,” said Bruce L.A. Carter, Ph.D., President and Chief Executive Officer of ZymoGenetics. “His strategic and operational skills will serve us well as we prepare for the commercialization of rhThrombin and continue to move our other products through clinical development.”
Dr. Himes joined ZymoGenetics in November 2005 as Vice President, Commercial Manufacturing Operations. Previously, Dr. Himes served as Vice President for Worldwide Manufacturing Operations for Corixa Corporation with responsibility for manufacturing operations, process development and quality control for all in-house and outsourced operations in support of commercial and clinical supplies. From 2000 to 2003, Dr. Himes served as Vice President of Manufacturing Operations for Targeted Genetics Corporation, where he was responsible for manufacturing and clinical supply operations including quality control, materials management and contract manufacturing for gene delivery products. From 1999 to 2000, Dr. Himes served as Vice President Product Development for Genovo, Inc. Prior to that, Dr. Himes held positions of increasing responsibility over ten years with Wyeth-Lederle Vaccines, including Associate Director of Biological Development, Manager of Viral Vaccine Development and Clinical Production, and Cell Culture Pilot Plant Supervisor. Dr. Himes received a Bachelors of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.
About ZymoGenetics
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics’ actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company’s public filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K for the year ended December 31, 2005. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
CONTACT: investors, John Calhoun, MD, MBA, Director, Corporate Communications & Investor Relations, +1-206-442-6744, or media, Susan W. Specht, MBA, Associate Director, Corporate Communications, +1-206-442-6592, both of ZymoGenetics, Inc.
ZymoGenetics, Inc.
CONTACT: investors, John Calhoun, MD, MBA, Director, CorporateCommunications & Investor Relations, +1-206-442-6744, or media, Susan W.Specht, MBA, Associate Director, Corporate Communications, +1-206-442-6592,both of ZymoGenetics, Inc.
Web site: http://www.zymogenetics.com//
